Day: February 28, 2022

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2021, and provided business highlights. “Denali is now transitioning to a late-stage development company, having made significant progress in advancing our clinical portfolio of product candidates for neurodegenerative and lysosomal storage diseases during 2021,” said Ryan Watts, Ph.D., Denali’s Chief Executive Officer. “In 2022, we plan to advance DNL151 and DNL310 into potentially registrational clinical trials for Parkinson’s disease and MPS II (Hunter syndrome), respectively, as well...

NASHVILLE, Tenn., Feb. 28, 2022 (GLOBE NEWSWIRE) — SmileDirectClub, Inc. (Nasdaq: SDC), the next generation oral care company with the first medtech platform for teeth straightening, today announced its financial results for the fourth quarter and year ended December 31, 2021. Fourth Quarter 2021 Financial HighlightsTotal revenue of $126 million, a decrease of 31.6% over the prior year period. Net loss of $(95) million, a decrease of $62 million over the prior year period. Adjusted EBITDA of $(62) million, a decrease of $69 million over the prior year period. Diluted EPS of $(0.25), a decrease of $0.16 over the prior year period.2021 Financial HighlightsFY 2021 total revenue of $638 million, a decrease of 2.9% over the prior year. Net loss of $(336) million, a decrease of $57 million over the prior year. Adjusted EBITDA...

MANCHESTER, NH, Feb. 28, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Minim, Inc. (NASDAQ: MINM), the creator of intelligent WiFi software and Motorola home networking products under an exclusive global brand license, today announces both an update to its Virtual Investor Day timing and a business update: Virtual Investor Day Minim previously announced that it would host a virtual investor day event, to be held on Feb 28, 2022, at 4:30 pm ET. With the announcement that it has appointed a new Chief Financial Officer, the Company now plans to reschedule the event to the second quarter. This postponement will allow the new CFO to fully participate in the investor day event. The new date for the investor day will be announced after the CFO starts with the Company on March 21, 2022. Business Update In lieu of the opportunity to update...

Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levels Durable serum TTR reductions observed with patient follow-up ranging from 2 to 12 months NTLA-2001 was generally well tolerated at all dose levels On track to initiate polyneuropathy dose-expansion cohort (Part 2) in Q1 2022 Intellia to host investor event today, Monday, February 28, at 4:30 p.m. ETCAMBRIDGE, Mass. and TARRYTOWN, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin...

CALGARY, Alberta, Feb. 28, 2022 (GLOBE NEWSWIRE) — Inventronics Limited (“Inventronics” or the “Corporation”) (IVX:TSX Venture) announces the grant of options to purchase common shares of the Corporation to members of the management team and Board of Directors of the Corporation. Each of the four members of Inventronics senior management team (“Management Group”) were granted 100,000 options and each of the two independent directors were granted 25,000 options, or in aggregate 450,000 options, to purchase common shares of Inventronics with an exercise price of $1.65 and an expiry date of five years from the date of grant. Three members of the Management Group are the majority shareholders of 1437891 Alberta Ltd., which holds a controlling interest in Inventronics amounting to approximately 73% of the issued and outstanding...

EDINBURGH, United Kingdom, Feb. 28, 2022 (GLOBE NEWSWIRE) — NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in two upcoming virtual investor conferences. Event: Cowen’s 42nd Annual Healthcare Conference Dates: March 7-9, 2022 Event: Oppenheimer’s 32nd Annual Healthcare Conference Presentation Date: Wednesday, March 16, 2022Presentation Time: 8:00 AM ET The presentation at Oppenheimer’s 32nd Annual Healthcare Conference will be webcast live and available for replay under “Events & Presentations” in the Investors section of the Company’s website at www.nucana.com. About NuCanaNuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying...

Enrollment Ongoing in Multi-dose, Multi-cycle Escalation Cohort of FT596+R at 900 Million Cells per Dose for R/R BCL; Interim Phase 1 Data of 16 Patients Showed 69% ORR and 56% CR in Single-dose Escalation Cohorts of FT596+R at ≥90 Million Cells Granted RMAT Designation for FT516 in R/R DLBCL; Enrollment Ongoing in Multi-dose, Multi-cycle Expansion Cohorts at 900 Million Cells per Dose in Disease-specific Indications, including Aggressive BCL in Patients Previously Treated with Autologous CD19-targeted CAR T-cell Therapy Initial FT819 Dose-Escalation Cohort Cleared with No DLTs for R/R BCL in Landmark Phase 1 Study of Off-the-shelf, iPSC-derived CAR T-cell Therapy Preclinical Milestone Reached for Second Product Candidate under Janssen Collaboration SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE),...

Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular dystrophy Total company revenue increased from $176.3 million in 2020 to $235.3 million in 2021SAN FRANCISCO, Feb. 28, 2022 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2021 and provided an update on the company’s recent developments. “We are excited to advance pamrevlumab in three high value indications – completing enrollment in our LAPIS and LELANTOS-1 Phase 3 studies, and expecting to complete enrollment of the ZEPHYRUS-1 Phase 3 study in idiopathic pulmonary fibrosis in the next few weeks,” said Enrique Conterno, Chief Executive Officer, FibroGen....

Prepared Remarks to be Webcast at 8:30 am ET CHICAGO, Feb. 28, 2022 (GLOBE NEWSWIRE) — Vivid Seats Inc. (NASDAQ:SEAT) (“Vivid Seats” or the “Company”), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, will report financial results for the fourth quarter and full year 2021 on Thursday, March 10, 2022, before the U.S. stock market opens. Management will discuss the results on a webcast at 8:30 a.m. ET. The live webcast and replay can be accessed at https://investors.vividseats.com/. About Vivid Seats Founded in 2001, Vivid Seats is a leading online ticket marketplace committed to becoming the ultimate partner for connecting fans to the live events, artists, and teams they love. Based on the belief that everyone...

TULSA, Okla., Feb. 28, 2022 (GLOBE NEWSWIRE) — AAON, INC. (NASDAQ-AAON), a leader in innovation and production of premium quality, highly energy efficient HVAC products for nonresidential buildings, today announced its results for the fourth quarter of 2021. AAON reported record fourth quarter revenue of $136.3 million, up 16.8% from the prior-year quarter. Price increases contributed approximately 10.0% to revenue growth in the quarter. However, gross profit declined 21.7% to $26.5 million, or 19.5% of sales. Gross profit was impacted by supply chain issues, which constrained production, led to operational inefficiencies and unabsorbed fixed costs, and exacerbated the adverse effects of inflation by slowing the turnover of our lower priced backlog and delaying the throughput of orders placed after recent price increases. This...